miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart

Future Medicinal Chemistry

Volumn 7, Issue 13, 2015, Pages 1771-1792

  Bernardo, Bianca C ^a   Ooi, Jenny Y Y ^a   Lin, Ruby C Y ^b,c   Mcmullen, Julie R ^a,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Asbestos Diseases Research Institute   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCINEURIN; LIPOSOME; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 15; MICRORNA 208A; MICRORNA 25; MICRORNA 29; MICRORNA 302; MICRORNA 367; NANOPARTICLE; PEPTIDE NUCLEIC ACID; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CALCIUM HOMEOSTASIS; CELL PROLIFERATION; CHEMICAL MODIFICATION; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HEART DISEASE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; MUSCLE CELL; NONVIRAL GENE DELIVERY SYSTEM; PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; ANIMAL; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART; PROCEDURES;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HEART; HUMANS; MICRORNAS; MYOCARDIUM;

EID: 84944411873     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.107     Document Type: Article

References (179)

1. Bernardo BC, Charchar FJ, Lin RCY, McMullen JR. A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ. 21(3), 131-142 (2012
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993
3. Wightman B, Ha I, Ruvkun G. Post-transcriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75(5), 855-862 (1993
4. Matkovich SJ, Hu Y, Dorn GW. Regulation of cardiac microRNAs by cardiac microRNAs. Circ. Res. 113(1), 62-71 (2013
5. Londin E, Loher P, Telonis AG et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primateand tissue-specific microRNAs. Proc. Natl Acad. Sci. USA. 112(10), E1106-E1115 (2015
6. miRBase. www.mirbase.org/
7. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15(8), 509-524 (2014
8. Felekkis K, Touvana E, Stefanou C, Deltas C. MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 14(4), 236-240 (2010
9. Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 75(1), 69-93 (2013
10. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 9(2), 102-114 (2008
11. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153(3), 654-665 (2013
12. Zhang C. MicroRNomics: a newly emerging approach for disease biology. Physiol. Genomics 33(2), 139-147 (2008
13. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther. 18(12), 1104-1110 (2011
14. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 921-928, (2015
15. Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. Nat. Struct. Mol. Biol. 19(3), 321-327 (2012
16. Hausser J, Syed AP, Bilen B, Zavolan M. Analysis of CDSlocated miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 23(4), 604-615 (2013
17. Brümmer A, Hausser J. MicroRNA binding sites in the coding region of mRNAs: extending the repertoire of posttranscriptional gene regulation. BioEssays 36(6), 617-626 (2014
18. Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions - beyond repression of gene expression. Nat. Rev. Genet. 15(9), 599-612 (2014
19. Dorn GW, Matkovich SJ, Eschenbacher WH, Zhang Y. A human 3 miR-499 mutation alters cardiac mRNA targeting and function. Circ. Res. 958-967, (2012
20. Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. Mol. Cell 38(6), 789-802 (2010
21. Martin HC, Wani S, Steptoe AL et al. Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs. Genome Biol. 15(3), R51 (2014
22. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004
23. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu. Rev. Path. Mech. 9(1), 287-314 (2014
24. Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol. 6(6), 590-610 (2012
25. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc. Res. 93(4), 583-593 (2011
26. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the MicroRNA perspective. Diabetes 60(7), 1832-1837 (2011
27. McClelland AD, Kantharidis P. MicroRNA in the development of diabetic complications. Clin. Sci. (Lond.) 126(2), 95-110 (2014
28. Winbanks CE, Ooi JY, Nguyen SS, McMullen JR, Bernardo BC. MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: potential drug targets?. Clin. Exp. Pharmacol. Physiol. 41(9), 727-737 (2014
29. Neppl RL, Wang D-Z. The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. Genes Dis. 1(1), 18-39 (2014
30. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITSCLIP decodes microRNA-mRNA interaction maps. Nature 460(7254), 479-486 (2009
31. Hafner M, Landthaler M, Burger L et al. Transcriptomewide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141(1), 129-141 (2010
32. Hafner M, Lianoglou S, Tuschl T, Betel D. Genome-wide identification of miRNA targets by PAR-CLIP. Methods 58(2), 94-105 (2012
33. Spitzer J, Hafner M, Landthaler M et al. PAR-CLIP (Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation): a step-by-step protocol to the transcriptome-wide identification of binding sites of RNAbinding proteins. Methods Enzymol. 539, 113-161 (2014
34. Ooi JYY, Bernardo BC, McMullen JR. The therapeutic potential of microRNAs regulated in settings of physiological cardiac hypertrophy. Future Medicinal Chemistry 6(2), 205-222 (2014
35. Boettger T, Braun T. A new level of complexity: the role of microRNAs in cardiovascular development. Circ. Res. 110(7), 1000-1013 (2012
36. Vickers KC, Rye KA, Tabet F. MicroRNAs in the onset and development of cardiovascular disease. Clin. Sci. (Lond.) 126(3), 183-194 (2014
37. Zhao Y, Ransom JF, Li A et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129(2), 303-317 (2007
38. Chen J-F, Murchison EP, Tang R et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl Acad. Sci. USA 105(6), 2111-2116 (2008
39. da Costa Martins PA, Bourajjaj M, Gladka M et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118(15), 1567-1576 (2008
40. Philippen LE, Dirkx E, da Costa-Martins PA, De Windt LJ. Non-coding RNA in control of gene regulatory programs in cardiac development and disease. J. Mol. Cell. Cardiol. 27, pii: S0022-2828(15)00100-5 (2015
41. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436(7048), 214-220 (2005
42. Liu N, Bezprozvannaya S, Williams AH et al. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22(23), 3242-3254 (2008
43. Chen JF, Mandel EM, Thomson JM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38(2), 228-233 (2006
44. Ventura A, Young AG, Winslow MM et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132(5), 875-886 (2008
45. Porrello ER, Johnson BA, Aurora AB et al. miR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ. Res. 109(6), 670-679 (2011
46. Ikeda S, He A, Kong SW et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 29(8), 2193-2204 (2009
47. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224), 980-984 (2008
48. Patrick DM, Montgomery RL, Qi X et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120(11), 3912-3916 (2010
49. Meloni M, Marchetti M, Garner K et al. Local inhibition of MicroRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 21(7), 1390-1402 (2013
50. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208(3), 549-560 (2011
51. Van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13027-13032 (2008
52. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol. Genomics 44(4), 237-244 (2012
53. Bernardo BC, Gao XM, Winbanks CE et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl Acad. Sci. USA 109(43), 17615-17620 (2012
54. Boon RA, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature 495(7439), 107-110 (2013
55. Care A, Catalucci D, Felicetti F et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13(5), 613-618 (2007
56. Castaldi A, Zaglia T, Di Mauro V et al. MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade. Circ. Res. 115(2), 273-283 (2014
57. Da Costa Martins PA, Salic K, Gladka MM et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an autoamplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12(12), 1220-1227 (2010
58. Van Rooij E, Sutherland LB, Qi XX, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316(5824), 575-579 (2007
59. Grueter CE, Van Rooij E, Johnson BA et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149(3), 671-683 (2012
60. Ucar A, Gupta SK, Fiedler J et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012
61. Aurora AB, Mahmoud AI, Luo X et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J. Clin. Invest. 122(4), 1222-1232 (2012
62. Ganesan J, Ramanujam D, Sassi Y et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogenactivated protein kinase pathway factors. Circulation 127(21), 2097-2106 (2013
63. Nagalingam RS, Sundaresan NR, Noor M, Gupta MP, Solaro RJ, Gupta M. Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor beta (TGFbeta1)-dependent paracrine mechanism. J. Biol. Chem. 289(39), 27199-27214 (2014
64. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy/novelty and significance. Circ. Res. 111(5), 521-531 (2012
65. Wang J-X, Jiao J-Q, Li Q et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med. 17(1), 71-78 (2011
66. Shieh JTC, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS ONE 6(5), e19481 (2011
67. Bernardo BC, Nguyen SS, Winbanks CE et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 28(12), 5097-5110 (2014
68. Bernardo BC, Ooi JYY, McMullen JR. The yin and yang of adaptive and maladaptive processes in heart failure. Drug Discov. Today 9(4), e163-e172 (2012
69. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128(1), 191-227 (2010
70. Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89(9), 1401-1438 (2015
71. Sayed D, Hong C, Chen I-Y, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100(3), 416-424 (2007
72. Van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103(48), 18255-18260 (2006
73. Hu Y, Matkovich SJ, Hecker PA, Zhang Y, Edwards JR, Dorn GW, 2nd. Epitranscriptional orchestration of genetic reprogramming is an emergent property of stress-regulated cardiac microRNAs. Proc. Natl Acad. Sci. USA 109(48), 19864-19869 (2012
74. Yang K-C, Yamada KA, Patel AY et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129(9), 1009-1021 (2014
75. Melman YF, Shah R, Das S. MicroRNAs in heart failure: is the picture becoming less mirky?. Circ. Heart Fail. 7(1), 203-214 (2014
76. Matkovich SJ, Wang W, Tu Y et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressureoverloaded adult hearts. Circ. Res. 106(1), 166-175 (2010
77. Matkovich SJ. MicroRNAs in the stressed heart: sorting the signal from the noise. Cells 3(3), 778-801 (2014
78. Dong D-l, Yang B-f. Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure. Acta. Pharmaceutica. Sinica. B 1(1), 1-7 (2011
79. Calway T, Kim GH. Harnessing the therapeutic potential of MicroRNAs for cardiovascular disease. J. Cardiovas. Pharmacol. Ther.131-143 (2014
80. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 106(11), 1675-1680 (2010
81. Pottier N, Cauffiez C, Perrais M, Barbry P, Mari B. FibromiRs: translating molecular discoveries into new antifibrotic drugs. Trends Pharmacol. Sci. 35(3), 119-126 (2014
82. Thum T. Noncoding RNAs and myocardial fibrosis. Nat. Rev. Cardiol. 11(11), 655-663 (2014
83. Liu G, Friggeri A, Yang Y et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207(8), 1589-1597 (2010
84. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 22(9), 1668-1681 (2011
85. Hatley ME, Patrick DM, Garcia MR et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18(3), 282-293 (2010
86. Skommer J, Rana I, Marques FZ, Zhu W, Du Z, Charchar FJ. Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death. Cell Death Dis. 5, e1325 (2014
87. Li P. MicroRNAs in cardiac apoptosis. J Cardiovasc. Transl Res. 3(3), 219-224 (2010
88. Katz MG, Fargnoli AS, Williams RD, Kendle AP, Steuerwald NM, Bridges CR. miRNAs as potential molecular targets in heart failure. Future Cardiol. 10(6), 789-800 (2014
89. Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci. Transl Med. 6(239), 239ps3 (2014
90. Van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11(11), 860-872 (2012
91. Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury/novelty and significance. Circ. Res. 110(1), 71-81 (2012
92. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010
93. Rayner KJ, Esau CC, Hussain FN et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478(7369), 404-407 (2011
94. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013
95. Latronico MV, Condorelli G. Therapeutic applications of noncoding RNAs. Curr. Opin. Cardiol. 30(3), 213-221 (2015
96. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13(8), 622-638 (2014
97. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12(11), 847-865 (2013
98. Beavers KR, Nelson CE, Duvall CL. MiRNA inhibition in tissue engineering and regenerative medicine. Adv. Drug Deliv. Rev.123-137 (2015
99. Jayaraj GG, Nahar S, Maiti S. Nonconventional chemical inhibitors of microRNA: therapeutic scope. Chem. Commun. 51(5), 820-831 (2015
100. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 6(7), 851-864 (2014
101. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068), 685-689 (2005
102. Esau C, Davis S, Murray SF et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3(2), 87-98 (2006
103. Grunweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents?. BioDrugs 21(4), 235-243 (2007
104. Bernardo BC, Gao XM, Tham YK et al. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. PLoS ONE 9(2), e90337 (2014
105. Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 452(7189), 896-899 (2008
106. Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNAantimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucl. Acids Res. 36(4), 1153-1162 (2008
107. Obad S, dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43(4), 371-378 (2011
108. Young JA, Ting KK, Li J et al. Regulation of vascular leak and recovery from ischemic injury by general and VEcadherin-restricted miRNA antagonists of miR-27. Blood 122(16), 2911-2919 (2013
109. Nielsen PE, Egholm M, Buchardt O. Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjug. Chem. 5(1), 3-7 (1994
110. Rozners E. Recent advances in chemical modification of peptide nucleic acids. J. Nucleic Acids 2012, 518162 (2012
111. Yin H, Lu Q, Wood M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16(1), 38-45 (2008
112. Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA. Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol. Ther. Nucleic Acids 2, e117 (2013
113. Hammond SM, McClorey G, Nordin JZ et al. Correlating in vitro splice switching activity with systemic in vivo delivery using novel ZEN-modified oligonucleotides. Mol. Ther. Nucleic Acids 3, e212 (2014
114. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Meth. 4(9), 721-726 (2007
115. Tay FC, Lim JK, Zhu H, Hin LC, Wang S. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv. Drug Delivery. Rev. 81(0), 117-127 (2015
116. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 16(11), 2043-2050 (2010
117. Kluiver J, Gibcus JH, Hettinga C et al. Rapid generation of microRNA sponges for microRNA inhibition. PLoS ONE 7(1), e29275 (2012
118. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, Van den Berg A. Generation of miRNA sponge constructs. Methods 58(2), 113-117 (2012
119. Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 37(6), e43 (2009
120. Sayed D, Rane S, Lypowy J et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19(8), 3272-3282 (2008
121. Liu Y, Han Y, Zhang H et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS ONE 7(12), e52280 (2012
122. Bak RO, Hollensen AK, Mikkelsen JG. Managing microRNAs with vector-encoded decoy-type inhibitors. Mol. Ther. 21(8), 1478-1485 (2013
123. Krol J, Busskamp V, Markiewicz I et al. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell 141(4), 618-631 (2010
124. Winbanks CE, Beyer C, Hagg A, Qian H, Sepulveda PV, Gregorevic P. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS ONE 8(9), e73589 (2013
125. Montgomery RL, Yu G, Latimer PA et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol. Med. 6(10), 1347-1356 (2014
126. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 3, 120 (2012
127. Lin RC, Van Zandwijk N, Reid G. MicroRNA therapeutics - back in vogue?. J. Investig. Genomics 2(1), 00012 (2014
128. Kwekkeboom RF, Lei Z, Doevendans PA, Musters RJ, Sluijter JP. Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin. Sci. (Lond.) 127(6), 351-365 (2014
129. Rothschild SI. MicroRNA therapies in cancer. Mol. Cell Ther 2, 7 (2014
130. Shim G, Kim M-G, Park JY, Oh Y-K. Application of cationic liposomes for delivery of nucleic acids. Asian J. Pharma. Sci. 8(2), 72-80 (2013
131. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650-1656 (2010
132. Cheng CJ, Bahal R, Babar IA et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107-110 (2015
133. Zacchigna S, Zentilin L, Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ. Res. 114(11), 1827-1846 (2014
134. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J. Clin. Invest. 123(1), 53-61 (2013
135. Jessup M, Greenberg B, Mancini D et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a Phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124(3), 304-313 (2011
136. Selot RS, Hareendran S, Jayandharan GR. Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations. Curr. Pharm. Biotechnol. 14(12), 1072-1082 (2014
137. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1), 23-36 (2013
138. Zsebo K, Yaroshinsky A, Rudy JJ et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ. Res. 114(1), 101-108 (2014
139. Garde D. Bristol-Myers bets big on gene therapy with a 1B uniQure deal. FierceBiotech (2015). www.fiercebiotech.com/story/bristol-myers-bets-big-genetherapy-1b-uniqure-deal/2015-04-06
140. Ritterhoff J, Most P. Targeting S100A1 in heart failure. Gene Ther. 19(6), 613-621 (2012
141. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin. Pharmacol. Ther. 93(1), 98-104 (2013
142. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 148(6), 1172-1187 (2012
143. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122 - a key factor and therapeutic target in liver disease. J. Hepatol. 62(2), 448-457 (2015
144. Weeks KL, McMullen JR. The athlete's heart vs. The failing heart: can signaling explain the two distinct outcomes?. Physiology 26(2), 97-105 (2011
145. McMullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100(21), 12355-12360 (2003
146. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104(2), 612-617 (2007
147. Lin RCY, Weeks KL, Gao X-M et al. PI3K(p110a) protects against myocardial infarction-induced heart failure/identification of PI3K-regulated miRNAs and mRNAs. Arterioscler. Thromb. Vasc. Biol. 30, 724-732 (2010
148. Greco S, Fasanaro P, Castelvecchio S et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61(6), 1633-1641 (2012
149. Thum T, Galuppo P, Wolf C et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116(3), 258-267 (2007
150. Murphy BL, Obad S, Bihannic L et al. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 73(23), 7068-7078 (2013
151. Porrello ER, Mahmoud AI, Simpson E et al. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl Acad. Sci. USA 110(1), 187-192 (2013
152. Wahlquist C, Jeong D, Rojas-Munoz A et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531-535 (2014
153. Dirkx E, Gladka MM, Philippen LE et al. NFAT and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat. Cell Biol. 15(11), 1282-1293 (2013
154. Bush EW, Van Rooij E. miR-25 in heart failure. Circ. Res. 115(7), 610-612 (2014
155. Porrello ER, Mahmoud AI, Simpson E et al. Transient regenerative potential of the neonatal mouse heart. Science 331(6020), 1078-1080 (2011
156. Yuan X, Liu C, Yang P et al. Clustered microRNAs' coordination in regulating protein-protein interaction network. BMC Syst. Biol. 3, 65 (2009
157. Tian Y, Liu Y, Wang T et al. A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci. Transl Med. 7(279), 279ra38 (2015
158. Callis TE, Pandya K, Seok HY et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119(9), 2772-2786 (2009
159. Montgomery RL, Hullinger TG, Semus HM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure/clinical perspective. Circulation 124(14), 1537-1547 (2011
160. Small EM, Frost RJA, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121(8), 1022-1032 (2010
161. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liverspecific MicroRNA. Science 309(5740), 1577-1581 (2005
162. Bichi R, Shinton SA, Martin ES et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99(10), 6955-6960 (2002
163. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 60, 167-179 (2009
164. Kasinski AL, Kelnar K, Stahlhut C et al. A combinatorial microRNA therapeutics approach to suppressing non-smallcell lung cancer. Oncogene3547-3555 (2014
165. Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget 5(4), 872-881 (2014
166. Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70(14), 5923-5930 (2010
167. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18(1), 181-187 (2010
168. Reid G, Pel ME, Kirschner MB et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 24(12), 3128-3135 (2013
169. MacDiarmid JA, Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr. Opin. Biotechnol. 22(6), 909-916 (2011
170. Peacock H, Kannan A, Beal PA, Burrows CJ. Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem. 76(18), 7295-7300 (2011
171. Watanabe Y, Kanai A. Systems biology reveals MicroRNAmediated gene regulation. Front. Genet. 2, 29 (2011
172. Moore MJ, Zhang C, Gantman EC, Mele A, Darnell JC, Darnell RB. Mapping argonaute and conventional RNAbinding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. Nat. Protocols 9(2), 263-293 (2014
173. Matkovich SJ, Dorn GW 2nd. Deep sequencing of cardiac microRNA-mRNA interactomes in clinical and experimental cardiomyopathy. Methods Mol. Biol. 1299, 27-49 (2015
174. Matkovich SJ, Van Booven DJ, Eschenbacher WH, Dorn GW, 2nd. RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ. Res. 108(1), 18-26 (2011
175. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 455(7209), 64-71 (2008
176. Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat. Protoc. 7(8), 1534-1550 (2012
177. Ingolia Nicholas T, Brar Gloria A, Stern-Ginossar N et al. Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes. Cell Reports 8(5), 1365-1379 (2015
178. Grosshans H, Filipowicz W. Proteomics joins the search for MicroRNA targets. Cell 134(4), 560-562 (2008
179. Gray WD, French KM, Ghosh-Choudhary SK et al. Identification of therapeutic covariant microRNA clusters in hypoxia treated cardiac progenitor cell exosomes using systems biology. Circ. Res. 116(2), 255-263 (2015